EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
Hwangbo Won, 이정현, 안상정, 김서진, 박경화, 김철환, 김인선,
소속 상세정보
( Hwangbo Won )
Korea University College of Medicine Korea University Anam Hospital Department of Pathology
이정현 ( Lee Jeong-Hyeon )
Korea University College of Medicine Korea University Anam Hospital Department of Pathology
안상정 ( Ahn Sang-Jeong )
Korea University College of Medicine Korea University Anam Hospital Department of Pathology
김서진 ( Kim Seo-Jin )
Korea University College of Medicine Korea University Anam Hospital Department of Pathology
박경화 ( Park Kyong-Hwa )
Korea University College of Medicine Korea University Anam Hospital Department of Pathology
김철환 ( Kim Chul-Hwan )
Korea University College of Medicine Korea University Anam Hospital Department of Pathology
김인선 ( Kim In-Sun )
Korea University College of Medicine Korea University Anam Hospital Department of Pathology
KMID : 0357920130470020107
Abstract
Background: The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment. Methods: A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification. Results: EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2+, EGFR+, cytokeratin 5/6? (CK5/6?) group, 11.2% of the HER-2?, EGFR+, CK5/6? group, and 19.1% of the HER-2?, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1+ expression cases, 15.9% of 2+ expression cases, and 38.5% of 3+ expression cases. In group 2, the tumors had a high Ki- 67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6. Conclusions: EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.
키워드
Breast neoplasms; Receptor; epidermal growth factor; Gene amplification; Protein expression
원문 및 링크아웃 정보
등재저널 정보